Therapeutic Approach

Ritter Pharmaceuticals’ CEO, Andrew J. Ritter to Present at the 11th Annual SoCalBio Investor and Partnership Conference

10. September 2009

LOS ANGELES – September 10, 2009 — Ritter Pharmaceuticals, Inc. (Ritter), a leader in gastrointestinal health, announced today that the Company’s President and Chief Executive Officer, Andrew J. Ritter, will be presenting at the 11th Annual SoCalBio Investor and Partnership Conference. The Conference is being held

Thursday, September 17, 2009 at The Loews Santa Monica Beach Hotel in Santa Monica, California. The Company is scheduled to present that day at 9:00 a.m. Pacific Time.

Background on Ritter Pharmaceuticals President and CEO, Andrew J. Ritter
Mr. Ritter has been studying the field of Lactose Intolerance for over 15 years and is considered a worldwide leading expert on the topic. He subsequently founded Ritter Pharmaceuticals, Inc. and engaged other leading Lactose Intolerance researchers to join his team in developing the first treatment for Lactose Intolerance.

About Ritter Pharmaceuticals
Ritter is committed to the discovery, development and commercialization of innovative therapies for gastrointestinal diseases. The Company’s scientific platform of gastrointestinal physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of GI diseases, including lactose intolerance, irritable bowel syndrome, Crohn’s disease, and ulcerative colitis. Ritter’s ultimate goal is to improve digestive health and overall quality of life.

Ritter’s first compound, RP-G28, has been developed for the treatment of lactose intolerance. RP-G28 will effectively stand out as the first FDA-approved drug for the treatment of lactose intolerance.

Related Posts